transFAL

orange__line

The transFAL project is a sub-study within the Parsifal clinical trial. The initial goal will be to analyze the molecular tumor profile at the time of progression in patients with moderate sensitivity to palbociclib in combination with first-line endocrine therapy. For this purpose, different molecular approaches, such as differential proteomics, in vivo PDX models, FISH, DNA sequencing, will be run on an initial subset of the Parsifal population.

NAME TUMOR TYPE TITLE PHASE N SITES COUNTRY STATUS
transFAL
Breast Prospective evaluation of predictive/prognostic biomarkers for palbociclib and endocrine therapy in ER positive HER2 negative advanced metastatic breast cancer within the PARSIFAL clinical trial. Sub-study 280 52 Spain, France, Italy, UK, Germany, Czech Republic, Russia Samples collection and analysis.